Study identifier:DC-452-0003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Effect of Cholesterol Lowering on the Progression of Aortic Stenosis in Patients with Mild to Moderate Aortic Stenosis (ASTRONOMER)Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin and The Sub-Study Protocol.
Aortic Stenosis
Phase 3
No
Rosuvastatin, Placebo
All
378
Interventional
18 Years - 82 Years
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Dec 2010 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
University of Ottawa Heart Institute
No locations available
Arms | Assigned Interventions |
---|---|
Active Comparator: 1 Rosuvastatin 40 mg | Drug: Rosuvastatin 40 mg, oral, single dose |
Placebo Comparator: 2 placebo | Drug: Placebo oral, single dose |